Comment on

• Presynaptic and postsynaptic modifications of the serotonin system by long-term administration of antidepressant treatments. An in vivo electrophysiologic study in the rat.

  Chaput Y, de Montigny C, Blier P. Chaput Y, et al. Neuropsychopharmacology. 1991 Dec;5(4):219-29. Neuropsychopharmacology. 1991. PMID: 1839498
• Postcocaine anhedonia. An animal model of cocaine withdrawal.

  Markou A, Koob GF. Markou A, et al. Neuropsychopharmacology. 1991 Jan;4(1):17-26. Neuropsychopharmacology. 1991. PMID: 2003866
• Olanzapine versus placebo and haloperidol: acute phase results of the North American double-blind olanzapine trial.

  Beasley CM Jr, Tollefson G, Tran P, Satterlee W, Sanger T, Hamilton S. Beasley CM Jr, et al. Neuropsychopharmacology. 1996 Feb;14(2):111-23. doi: 10.1016/0893-133X(95)00069-P. Neuropsychopharmacology. 1996. PMID: 8822534 Clinical Trial.
• Dissociable deficits in the decision-making cognition of chronic amphetamine abusers, opiate abusers, patients with focal damage to prefrontal cortex, and tryptophan-depleted normal volunteers: evidence for monoaminergic mechanisms.

  Rogers RD, Everitt BJ, Baldacchino A, Blackshaw AJ, Swainson R, Wynne K, Baker NB, Hunter J, Carthy T, Booker E, London M, Deakin JF, Sahakian BJ, Robbins TW. Rogers RD, et al. Neuropsychopharmacology. 1999 Apr;20(4):322-39. doi: 10.1016/S0893-133X(98)00091-8. Neuropsychopharmacology. 1999. PMID: 10088133 Clinical Trial.
• Neurobehavioral effects of interferon-alpha in cancer patients: phenomenology and paroxetine responsiveness of symptom dimensions.

  Capuron L, Gumnick JF, Musselman DL, Lawson DH, Reemsnyder A, Nemeroff CB, Miller AH. Capuron L, et al. Neuropsychopharmacology. 2002 May;26(5):643-52. doi: 10.1016/S0893-133X(01)00407-9. Neuropsychopharmacology. 2002. PMID: 11927189 Clinical Trial.
• Cell proliferation in adult hippocampus is decreased by inescapable stress: reversal by fluoxetine treatment.

  Malberg JE, Duman RS. Malberg JE, et al. Neuropsychopharmacology. 2003 Sep;28(9):1562-71. doi: 10.1038/sj.npp.1300234. Epub 2003 Jul 2. Neuropsychopharmacology. 2003. PMID: 12838272
• Three-year outcomes in deep brain stimulation for highly resistant obsessive-compulsive disorder.

  Greenberg BD, Malone DA, Friehs GM, Rezai AR, Kubu CS, Malloy PF, Salloway SP, Okun MS, Goodman WK, Rasmussen SA. Greenberg BD, et al. Neuropsychopharmacology. 2006 Nov;31(11):2384-93. doi: 10.1038/sj.npp.1301165. Epub 2006 Jul 19. Neuropsychopharmacology. 2006. PMID: 16855529 Clinical Trial.
• Deep brain stimulation to reward circuitry alleviates anhedonia in refractory major depression.

  Schlaepfer TE, Cohen MX, Frick C, Kosel M, Brodesser D, Axmacher N, Joe AY, Kreft M, Lenartz D, Sturm V. Schlaepfer TE, et al. Neuropsychopharmacology. 2008 Jan;33(2):368-77. doi: 10.1038/sj.npp.1301408. Epub 2007 Apr 11. Neuropsychopharmacology. 2008. PMID: 17429407
• Putting the efficacy of psychiatric and general medicine medication into perspective: review of meta-analyses.

  Leucht S, Hierl S, Kissling W, Dold M, Davis JM. Leucht S, et al. Br J Psychiatry. 2012 Feb;200(2):97-106. doi: 10.1192/bjp.bp.111.096594. Br J Psychiatry. 2012. PMID: 22297588 Review.